Abstract

Immunotherapy of malignant tumor is a verified and crucial anti-tumor strategy to help patients with cancer for prolonging prognostic survival. It is a novel anticancer tactics that activates the immune system to discern and damage cancer cells, thereby prevent them from proliferating. However, immunotherapy still faces many challenges in view of clinical efficacy and safety issues. Various nanomaterials, especially gold nanoparticles (AuNPs), have been developed not only for anticancer treatment but also for delivering antitumor drugs or combining other treatment strategies. Recently, some studies have focused on AuNPs for enhancing cancer immunotherapy. In this review, we summarized how AuNPs applicated as immune agents, drug carriers or combinations with other immunotherapies for anticancer treatment. AuNPs can not only act as immune regulators but also deliver immune drugs for cancer. Therefore, AuNPs are candidates for enhancing the efficiency and safety of cancer immunotherapy.

Highlights

  • OF IMMUNOTHERAPY AND NANOPARTICLESCancer immunotherapy has rapidly emerged in the past few years (Hegde and Chen, 2020)

  • Gold Nanoparticles in Cancer Immunotherapy the other hand, traditional immune stimulants lack the ability to target solid tumor tissue that results from many factors, including the tumor microenvironment (TME), immune evasion processes, and pharmacokinetics (Connor and Broome, 2018; Tan et al, 2020; Yang et al, 2021)

  • The authors showed that CM from ovarian CCs, CAFs, or ECs themselves induced tube formation and migration of ECs in vitro. These results prove that AuNPs inhibit angiogenesis by blocking vascular endothelial growth factor (VEGF)-VEGFR2 signaling from TME cells to endothelial cells

Read more

Summary

Introduction

OF IMMUNOTHERAPY AND NANOPARTICLESCancer immunotherapy has rapidly emerged in the past few years (Hegde and Chen, 2020). Gold Nanoparticles in Cancer Immunotherapy the other hand, traditional immune stimulants lack the ability to target solid tumor tissue that results from many factors, including the tumor microenvironment (TME), immune evasion processes, and pharmacokinetics (Connor and Broome, 2018; Tan et al, 2020; Yang et al, 2021).

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call